Drug
Sapropterin Dihydrochloride
Sapropterin Dihydrochloride: highest development phase Approved, developed by Aurobindo, BioMarin Pharmaceutical. 10 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Aurobindo, BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAPROPTERIN DIHYDROCHLORIDE | Approved | |
| Sapropterin Dihydrochloride NCT00272792 | Phase 3 | Phenylketonurias |
| sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin NCT00104247 | Phase 3 | Phenylketonurias |
| sapropterin dihydrochloride NCT00225615 | Phase 3 | Phenylketonurias |
| sapropterin dihydrochloride NCT00104260 | Phase 2 | Phenylketonurias |
| Sapropterin Dihydrochloride NCT00445978 | Phase 2 | Sickle Cell Disease |
| Sapropterin Dihydrochloride NCT00532844 | Phase 2 | Endothelial Dysfunction |
| sapropterin dihydrochloride NCT00789568 | Phase 1 | Phenylketonuria |
| sapropterin dihydrochloride (6R-BH4) NCT00435331 | Phase 1 | Pulmonary Arterial Hypertension |
| sapropterin dihydrochloride NCT01141595 | Not Applicable | Autism Spectrum Disorder |
Latest
No recent events.
Follow Sapropterin Dihydrochloride on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.